Eli Lilly: Sofe-M combined with bevacizumab treated ovarian cancer, with an objective response rate of 79%.

Zhitongcaijing · 3d ago
Eli Lilly: Sofe-M combined with bevacizumab treated ovarian cancer, with an objective response rate of 79%.